METHODS OF TREATING METAL OXIDE SURFACES AND SURFACES PRODUCED THEREBY
    1.
    发明申请
    METHODS OF TREATING METAL OXIDE SURFACES AND SURFACES PRODUCED THEREBY 审中-公开
    处理金属氧化物表面和生产的表面的方法

    公开(公告)号:WO2011106451A1

    公开(公告)日:2011-09-01

    申请号:PCT/US2011/025954

    申请日:2011-02-23

    Abstract: Methods for activating and/or reactivating a metal oxide surface for deposition, immobilizing, and/or growing a biological sample (e.g., an oligonucleotide, a polynucleotide, functionalized particle, a polymer, etc.) thereon are disclosed. The metal oxide surface (e.g., zirconium oxide) can be activated and/or reactivated by exposing the metal oxide surface to various activation and/or treatment protocols capable of enhancing a slide's activity relative to the activity of an untreated slide. The activation and/or treatment protocol can include subjecting the slide (or at least the metal oxide layer) to an oxygen plasma treatment and/or a peroxide solution for an amount of time sufficient to activate and/or reactivate the metal oxide surface. Activated sequencing slides capable of incorporation, for example, into various embodiments of a flow cell for use in NGS platforms are also disclosed herein.

    Abstract translation: 公开了用于活化和/或重新激活用于在其上沉积,固定和/或生长生物样品(例如寡核苷酸,多核苷酸,官能化颗粒,聚合物等)的金属氧化物表面的方法。 金属氧化物表面(例如,氧化锆)可以通过将金属氧化物表面暴露于能够相对于未处理载玻片的活性增强载玻片的活性的各种活化和/或处理方案而被活化和/或再活化。 活化和/或处理方案可以包括使载玻片(或至少金属氧化物层)经历氧等离子体处理和/或过氧化物溶液足以活化和/或重新活化金属氧化物表面的时间量。 本文还公开了能够并入例如用于NGS平台的流动池的各种实施方案中的活化测序载玻片。

    4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES
    2.
    发明申请
    4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES 审中-公开
    4-苯基氨基 - 喹唑啉-6-基 - 酰胺

    公开(公告)号:WO2005107758A1

    公开(公告)日:2005-11-17

    申请号:PCT/IB2005/001139

    申请日:2005-04-25

    CPC classification number: C07D239/94 C07D401/12 C07D403/12

    Abstract: The invention provides quinazoline compounds of the formula: wherein R 1 is halo; R 2 is H or halo; R 3 is a) C 1 -C 3 alkyl, optionally substituted by halo; or b) -(CH 2 ) n -morpholino, -(CH 2 ) n -piperidine, -(CH 2 ) n -piperazine, -(CH 2 ) n -piperazine-N(C 1 -C 3 alkyl), -(CH 2 ) n -pyrrolidine, or -(CH 2 ) n imidazole; n is 1 to 4; R 4 is -(CH 2 ) m -Het; Het is morpholine,piperidine, piperazine, piperazine-N(C 1 -C 3 alkyl), imidazole,pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH 2 , NH(C 1 -C 3 alkyl) or N (C 1 -C 3 alkyl) 2 ; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

    Abstract translation: 本发明提供下式的喹唑啉化合物:其中R1是卤素; R2是H或卤素; R3是a)任选被卤素取代的C 1 -C 3烷基; 或(b) - (CH 2)n - 吗啉代, - (CH 2)n - 哌啶, - (CH 2)n-哌嗪, - (CH 2)n - 哌嗪-N(C 1 -C 3烷基), - (CH 2) ,或 - (CH 2)n咪唑; n为1至4; R4是 - (CH2)m-Het; Het是吗啉,哌啶,哌嗪,哌嗪-N(C 1 -C 3烷基),咪唑,吡咯烷,氮杂环庚烷,3,4-二氢-2H-吡啶或3,6-二氢-2H-吡啶,各自任选被烷基 ,卤素,OH,NH 2,NH(C 1 -C 3烷基)或N(C 1 -C 3烷基)2; m为1-3; X为O,S或NH; 或其药学上可接受的盐,以及制备它们的方法和中间体化合物,有用的药物组合物和使用该化合物治疗增殖性疾病的方法。

Patent Agency Ranking